STOCK TITAN

Diamedica Therapeutics Inc SEC Filings

DMAC NASDAQ

Welcome to our dedicated page for Diamedica Therapeutics SEC filings (Ticker: DMAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Wondering how Phase II stroke data or kidney trial cash needs show up in DiaMedica Therapeutics’ SEC documents? Most investors start with the DiaMedica Therapeutics quarterly earnings report 10-Q filing to gauge burn rate, then hunt for DiaMedica Therapeutics insider trading Form 4 transactions that might signal confidence ahead of clinical readouts. We bring those documents together and layer each with AI-powered summaries so understanding DiaMedica Therapeutics SEC documents with AI becomes a five-minute task, not an afternoon.

Use Stock Titan’s dashboard to jump straight to the section you need:

  • 10-K & 10-Q – cash runway, DM199 development costs, risk factors (DiaMedica Therapeutics annual report 10-K simplified)
  • 8-K – trial milestones and partnerships (DiaMedica Therapeutics 8-K material events explained)
  • Form 4 – real-time alerts on DiaMedica Therapeutics Form 4 insider transactions real-time and DiaMedica Therapeutics executive stock transactions Form 4
  • DEF 14A – board pay and DiaMedica Therapeutics proxy statement executive compensation
Each document is tagged, searchable, and paired with concise AI notes for quick DiaMedica Therapeutics earnings report filing analysis.

Because DMAC is a single-asset biotech, a single footnote can shift valuation. Our AI flags new safety signals, partnership revenue, or shelf-registration clues the moment they appear. Whether you need dilution forecasts before the next raise or a recap of stroke trial endpoints, you’ll find DiaMedica Therapeutics SEC filings explained simply—updated the instant they hit EDGAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
current report

FAQ

What is the current stock price of Diamedica Therapeutics (DMAC)?

The current stock price of Diamedica Therapeutics (DMAC) is $4.18 as of July 18, 2025.

What is the market cap of Diamedica Therapeutics (DMAC)?

The market cap of Diamedica Therapeutics (DMAC) is approximately 157.4M.

What is the primary focus of DiaMedica Therapeutics Inc?

DiaMedica Therapeutics Inc focuses on developing innovative therapeutics for conditions with significant unmet clinical needs, particularly targeting chronic kidney disease and acute ischemic stroke.

What is DM199 and why is it important?

DM199 is a recombinant form of human tissue kallikrein-1, representing a novel approach to therapy in areas where few effective treatments exist, highlighting the company’s innovative research in biotechnology.

How does DiaMedica Therapeutics generate value?

The company advances its pipeline through rigorous clinical development, emphasizing scientific validation and milestone achievements rather than immediate revenue generation.

What makes DMAC distinct in the biopharmaceutical landscape?

DMAC distinguishes itself by targeting diseases with significant unmet needs using innovative recombinant therapeutics, underpinned by strong scientific research and a focused clinical development strategy.

Which disease areas does the company primarily address?

The company primarily addresses chronic kidney disease and acute ischemic stroke, aiming to provide novel treatment options where current therapies are limited or unavailable.

What is the research and development approach at DMAC?

DMAC employs a robust R&D strategy that integrates advanced biotechnology platforms and early-phase clinical trials to assess safety and efficacy, ensuring that its products are developed with scientific rigor.

How does DiaMedica Therapeutics compare to its competitors?

While competitors in the biopharmaceutical field may also focus on difficult-to-treat conditions, DMAC differentiates itself through its specialized focus on recombinant protein therapeutics and targeting of high unmet clinical need areas.

What can investors expect regarding the company’s strategy?

Investors can expect DMAC to continue concentrating on innovative therapeutic approaches and clinical development strategies focused on areas with limited treatment options, all supported by scientific expertise.
Diamedica Therapeutics Inc

NASDAQ:DMAC

DMAC Rankings

DMAC Stock Data

157.38M
26.09M
26.12%
34.19%
0.59%
Biotechnology
Pharmaceutical Preparations
Link
United States
MINNEAPOLIS